Sofinnova Ventures — Full Portfolio

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUGUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSKSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in

Board seatDKDavid Kabakoff· per SEC Form D

Co-investorsBABay City CapitalCACanaan PartnersLALAVLILilly Asia VenturesPFPfizer Venture InvestmentsQUQuan Capital+4 more

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

DZDaphne Zohar(Founder, CEO and Board Member)inMCMichael Chen(Executive Officer)inLGLana Gladstein(Executive Officer)inALAntony Loebel(Executive Officer)inEGEric Green(Executive Officer)in

Board seatJames I. Healy· per SEC Form D

Co-investorsARARCH Venture PartnersFOForesite CapitalHAHAWKTAILPUPureTech HealthTHThird Rock Ventures

Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.

BiotechDigital HealthMedical DevicesSouth San Francisco, US

Marshall Fordyce(Executive Officer, Director)in

BoardBSBeth Seidenberg(Director)inKVKurt von Emster(Director)inPEPatrick Enright(Director)inAndrew Cheng(Director)

Board seatMKMaha Katabi· per SEC Form D

Co-investorsKLKleiner PerkinsLOLongitude CapitalABAbingworthSOSofinnova Venture Partners

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)SDStuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHDHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)

Co-investorsAIAisling CapitalAPAPERTURE Venture PartnersF-F-Prime CapitalFOForesite CapitalRARA CapitalSOSofinnova Venture Partners+1 more

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome.

BiotechHealthtechPortola Valley, US

AVAlexandre Vamvakides(Executive Officer)Axel Paeger(Board Member (founder))Harvey Lalach(Executive Officer, Director)inGeorge Tidmarsh(Executive Officer, Director)Terrie Kellmeyer(Interim Chief Executive Officer)inCUChristopher U. Missling(Executive)in

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

PSPaul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)

BoardANAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)

Co-investorsCACardinal PartnersECEcoR1 CapitalDODomain AssociatesDODomain PartnersPOPolaris PartnersSASamsara BioCapital+1 more

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

DEDr. Edgar G. Engleman(Founder)

Co-investorsPFPfizer Venture InvestmentsRARA CapitalSASamsara BioCapitalVIVivo CapitalNANan Fung Life SciencesNONovo Holdings+3 more

Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.

BiotechHealthtechMedical DevicesRedwood City, US

DMDennis M. Lanfear(Executive Officer, Director)DLDenny Lanfear(Founder)inAlan C. Herman(Executive Officer)inJean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)

Co-investorsF-F-Prime CapitalHEHEALTHCARE ROYALTY PARTNERSVEVenrock

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

FZFeng Zhang(Scientific Founder, Core Member, Broad Institute of MIT and Harvard)inGCGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDLDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKBKatrine Bosley(Executive Officer, Director)inVMVic Myer(Executive Officer)in

Co-investorsECEcoR1 CapitalDEDeerfield Management CompanyFLFlagship VenturesPOPolaris Partners

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need.

Biotech

JRJay R. Luly(President, Director and Chief Executive Officer)Yat Sun Or(Chief Scientific Officer)STScott T. Rottinghaus(Chief Medical Officer)inMatthew P. Kowalsky(Chief Legal Officer and Corporate Secretary)TLTara L. Kieffer(Chief Product Strategy Officer)inBLBrendan Luu(Chief Business Officer)in

Co-investorsABAbbVie

Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions.

BiotechMedical DevicesHamilton

THOMAS W BEETHAM(Executive Officer)inSKSanj K. Patel(Chief Executive Officer and Chairman of the Board)

BoardSTEPHEN R BIGGAR(Director)FELIX J BAKER(Director)G. BRADLY COLE(Director)RICHARD S LEVY(Director)

Co-investorsDEDeerfield Management CompanySOSofinnova Venture Partners

Ligand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies.

BiotechFintechLa Jolla, US

BBBrook Byers(Co-founder)inMWMATTHEW W. FOEHR(Director)JLJOHN L. HIGGINS(Executive Officer, Director)inMATTHEW KORENBERG(Director)inCSCHARLES S. BERKMAN(Director)inTodd Davis(Chief Executive Officer)in

Co-investorsSISignet Healthcare PartnersVEVenrock

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

MRMatthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsBABain Capital Life SciencesCHCheyenne VenturesCLClaremont Creek VenturesFOForesite CapitalHAHarmony PartnersLILightspeed Venture Partners+2 more

Hugh Griffith(Founder)in

Co-investorsSCScottish Enterprise

Protalix is a biopharmaceutical company that develops and manufactures innovative pharmaceutical products, including treatments for orphan and rare diseases.

BiotechHealthtechMedical DevicesKarmiel, IL

Moshe Bashan(President and Chief Executive Officer)DBDror Bashan(President and Chief Executive Officer, Director)in

Co-investorsPOPontifax Venture Capital

Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.

BiotechDun Laoghaire, Co. Dublin, US

TBTran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)KLKarin L. Walker(Executive Officer)inTara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)CDCarol D. Karp(Executive Officer)in

Co-investorsINInvescoRARA CapitalWEWellington Management

Rapport is a biopharmaceutical company developing novel therapeutics.

BiotechHealthtechMedical Devices

ACAbe Ceesay(President)CGCheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)

Co-investorsARARCH Venture PartnersCACapital GroupJOJohnson & Johnson Innovation – JJDCTHThird Rock Ventures

Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

MHMatthew Henn(President and Chief Scientific Officer)inJohn Aunins(Executive Officer)inEDEric D. Shaff(Executive Officer)inDCDavid Cook(Executive Officer)inRJRoger J. Pomerantz(Executive Officer, Director)inRichard N. Kender(Executive Chair and Interim Chief Executive Officer)

Co-investorsFLFlagship PioneeringRARA CapitalFIFidelity Investments

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)inAMArlene Morris(Executive Officer, Director)inMAMichael A. Metzger(Chief Executive Officer)inKAKeith A. Goldan(Chief Financial Officer)in

BoardDPDennis Podlesak(Director)inIvor Royston(Director)

Co-investorsFOForesite CapitalPAPappas CapitalVEvenBio PartnersBLBlackRockDODomain AssociatesMPMPM BioImpact

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

BCBharatt Chowrira(Executive Officer)inMSMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)inPMPaul Miller(Executive Officer)inABAoife Brennan(Executive Officer)inTSTodd Shegog(Executive Officer)in

Co-investorsATAtlas VentureNENew Enterprise Associates (NEA)NSNSG VenturesPFPfizer Venture InvestmentsSOSolasta VenturesOROrbiMed

Aledia develops next-generation MicroLED display technology based on 3D nanowires grown on silicon, operating a pilot line and high-volume production facility.

Deep TechHardwareSemiconductorsGrenoble, FR

PGphilippe GILET(Founder)in

Co-investorsBRBraemar Energy VenturesINIntel CapitalDEDemeterINIngka InvestmentsSUSupernovaTETEL Venture Capital, Inc.+3 more

ASSIA develops core technology for broadband internet access and network optimization, serving telecommunications service providers and network operators.

AI & Machine LearningCloud ComputingData & InfrastructureDeep TechEnterprise SoftwareRedwood City, US

JMJohn M. Cioffi(CEO and Chairman of the Board)inACAssia Cioffi(Executive Vice President and Co-founder)in

Co-investorsDTDTCPSOSofinnova PartnersSTStanford UniversitySWSwisscom VenturesPAPartners for GrowthPAPartners for Growth (PFG)

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

SVShane V. Hegarty(Chief Scientific Officer & Co-Founder)inJSJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJIJeff Imbaro(Chief Operating Officer)inTSTiasha Shafiq(Chief of Staff)in

BoardCorey . Goodman(Director)inJLJonathan Leff(Director)in

Co-investorsVEvenBio PartnersMRMRL Ventures FundCICivilization Ventures Management, LlcCRCreative Destruction Lab (CDL)HAHatteras Venture PartnersIAIaso Ventures+7 more

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.

BiotechHealthtechMedical DevicesSan Francisco, US

Yi Larson(Founder and CEO)GGGeoff Gilmartin(Chief Medical Officer)EHEric Hu(Chief Business Officer)

Co-investorsFOForbionNONovo HoldingsSASanofi Ventures

Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.

AI & Machine LearningBiotechDefense TechGovTechGaithersburg, IL

Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)in

BoardEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)

Board seatJLJonathan Leff· per SEC Form D · $30M raise · filed Jun 2023

Co-investorsHAHackensack Meridian Health Bear's DenMAMaryland TEDCOTETEDCOAMAMR Action Fund

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.

BiotechBerkeley, US

Allison J. Hulme(CEO & President)inJKJohn Kincaid(Chief Scientific Officer)inDRDavis Ryman(Executive Officer)inMZMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)

Board seatLELars Ekman· per SEC Form D

Co-investorsCOCoastCapCTCTI Life Sciences Fund L.P.FJFJ LabsVEvenBio PartnersAPApollo Health VenturesVEvenBio Global Strategic

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

KYKarl Y. Hostetler(Executive Officer, Director)inGMGail Maderis(Director)inKBKristine Ball(President & CEO)inECElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRGRaju Gadiraju(Executive Officer)in

Board seatDKDavid Kabakoff· per SEC Form D

Co-investorsADAdjuvant CapitalBRBrace PharmaCACanaan PartnersLULumira VenturesMPMPM BioImpactOUOUP (Osage University Partners)+3 more

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Z(Zhengbin (Bing) Yao(Executive Officer, Director)inBRBrent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Board seatJames Healy· per SEC Form D

Co-investorsCACatalio Capital Management, LPFOForesite CapitalGEGeneral CatalystHOHongShan Capital GroupLALAVLILilly Asia Ventures+2 more

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)AMAlana McNulty(Executive Officer)in

BoardSimeon George(Director)JRJonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Board seatMKMaha Katabi· per SEC Form D · $56M raise · filed Feb 2016

Co-investorsASAstellas Venture Management LLCMIMission Bay CapitalMIMission BiocapitalOUOUP (Osage University Partners)PFPfizer Venture InvestmentsUSUS Venture Partners

Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.

BiotechHealthtechSan Diego, US

Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)

BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)

Board seatJLJonathan Leff· per SEC Form D · $189.2M raise · filed Oct 2023

Co-investorsF-F-Prime CapitalNONorwest Venture PartnersRIRiverVest Venture Partners

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.

BiotechDeep TechHealthtechSouth San Francisco, US

Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)

BoardPNPerry Nisen(Executive Officer, Director)inMFMaria Fardis(Director)inRJRajul Jain(Director)in

Board seatMKMaha Katabi· per SEC Form D

Co-investorsLOLongitude CapitalVIVida VenturesBIBiotechnology Value FundFRFrazier Life Sciences

Seattle, US

Ronald Seubert(Executive Officer, Director, Promoter)ECEvan Castiglia(Executive Officer)inJVJoseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)

BoardRSRobert Shepler(Director)in

Board seatDKDavid Kabakoff· per SEC Form D · $35.7M raise · filed Jul 2023

Co-investors5A5AM VenturesARArboretum VenturesF-F-Prime CapitalTETelegraph Hill Partners

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

KSKen Song(Executive Officer, Director)inBHBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)

BoardARAaron Royston(Director)in

Board seatMKMaha Katabi· per SEC Form D

Co-investorsSASamsara BioCapitalSCScion Life SciencesTCTCG CrossoverVEvenBio PartnersVEVersant VenturesVIVivo Capital+1 more

Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.

BiotechHardwareHealthtechMedical DevicesSan Mateo, US

Dr. Chou(Founder & Chief Executive Officer)CLCindy Lynch(Executive Officer)inTCTony Chou(Executive Officer, Director)in

BoardJLJack Lasersohn(Director)inTamir Meiri(Director)JRJonathan Root(Director)in

Board seatNoel Jee· per SEC Form D · $50M raise · filed Apr 2026

Co-investorsNONorwest Venture PartnersRURunway Growth CapitalUSUS Venture PartnersTHThe Vertical Group

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

ARAdam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)SRScott Robertson(Executive Officer)inGary Patou(Executive Officer)in

Board seatMKMaha Katabi· per SEC Form D

Co-investorsFRFrazier Life SciencesOROrbiMedRARA CapitalSASanofi VenturesAGAgent CapitalBLBlue Owl Capital+9 more

A pharmaceutical company that develops medicines and vaccines for patients globally.

BiotechHealthtechMedical DevicesCambridge, US

WYLIE W. VALE(Director)JKJOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)RSROBERT STEININGER(Executive Officer)inKEVIN F. MCLAUGHLIN(Executive Officer)inMLMATTHEW L. SHERMAN(Executive Officer)

Co-investorsBEBessemer Venture PartnersFOForesite CapitalLILightstone VenturesLOLowercarbon CapitalVEVenrockCOCollaborative Fund

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BLBRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)DEDavid Endicott(CEO of Alcon)in

Co-investorsALAlta PartnersAVAvoro Capital AdvisorsFOForesite CapitalOUOUP (Osage University Partners)

BiotechHealthtech

BiotechCincinnati, US

RSRobert Shalwitz(Executive Officer)JGJoseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)Ian A.W. Howes(Executive Officer)

Co-investorsCICincyTechOROrbiMed

AFYX is a biopharmaceutical company focused on reformulation and repurposing of existing pharmaceuticals for conditions including head and neck cancer, labor induction, cluster headaches, and pain and addiction.

BiotechHealthtechMedical DevicesHørsholm, DK

DCDr. Claus J. Møller-San Pedro(CEO)

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsBABain Capital Life SciencesRARA Capital

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

ESEmmanuel Simons(Executive Officer, Director)WSwilliam sewell(Founder)in

BoardEMEd Mathers(Director)inKPKush Parmar(Director)in

Co-investors5A5AM VenturesECEcoR1 CapitalNENew Enterprise Associates (NEA)RARA CapitalCOCowen Healthcare InvestmentsFIFidelity Investments+1 more

BiotechHealthtechMedical Devices

Co-investorsNENew Enterprise Associates (NEA)

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

CQCarlos Quezada-Ruiz(Chief Medical Officer)in

Co-investorsBABain Capital Life SciencesTCTCG Crossover

Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.

BiotechHealthtechMedical Devices

Co-investorsAVAvoro Capital AdvisorsFOFountain Healthcare PartnersLOLongitude CapitalSISignet Healthcare Partners

Anesiva is a biopharmaceutical company developing Nexletol for diet management.

Biotech

Anthera produces makeup and skincare products made in France with natural, non-toxic ingredients that are cruelty-free and vegan.

ConsumerWellness & FitnessFrance, FR

Co-investorsVAVantagePoint Capital Partners

Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechBurlingame, US

Mingxi Li(CEO)inFAFred Aswad(Chief Scientific Officer)in

Co-investorsPAPanacea Venture

Co-investorsAVAvoro Capital AdvisorsEPEpidarex CapitalF-F-Prime CapitalKEKeyhorse CapitalSOSolasta VenturesVEvenBio Partners

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

NRNils Regge(Co-Founder & General Partner)in

Co-investorsBLBLN CapitalCOCoastCapFJFJ LabsKFKfW CapitalTRTruVenturo GmbHCTCTI Life Sciences Fund L.P.+3 more

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAIAisling CapitalDEDecheng CapitalDRDroia VenturesECEcoR1 CapitalFOForesite CapitalSLSLVC+2 more

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

JMJan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)MAMartin Auster(Executive Officer)in

Co-investorsVIVivo CapitalAIAisling CapitalAVAvoro Capital AdvisorsFOForesite CapitalRARA Capital

A biotechnology company developing new therapies for patients with high unmet medical needs.

Biotech

Co-investorsDODolby Family Ventures

Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases that cause vision loss.

BiotechDeep TechMedical DevicesAustin, US

Co-investorsLILightstone VenturesHAHatteras Venture Partners

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

ACAthena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDEDelos CapitalFOForesite CapitalININCE CapitalLOLongwood FundNENew Enterprise Associates (NEA)OROrbiMed+3 more

BiotechSan Leandro, US

SASteve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)inSWStephen W. Lau(President, Chief Executive Officer, and Treasurer)inKSKenneth Schwartz(Executive Officer)inEYEric Yuen(Executive Officer)inMarten Steen(Director)in

Co-investorsHEHealthCapINInkefSESectoral Asset ManagementYSYsios Capital

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

ABAdrian Bot(Executive Officer)LSLaura Shawver(Executive Officer, Director)inRFRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsPFPfizer Venture InvestmentsRARA CapitalVIVida Ventures

BiotechNewton Centre, US

Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)

BoardScott Minick(Director)inTTTodd T. Foley(Director)inVincent Miles(Director)AKAnsbert K. Gadicke(Director)in

Co-investorsHEHEALTHCARE ROYALTY PARTNERSABAbingworthMPMPM BioImpact

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

MKMark Keating, MD(Co-founder)KNKotaro Nakanishi, PhD(Co-founder)YTYukihide Tomari, PhD(Co-founder)PZPhillip Zamore, PhD(Co-founder)

Co-investorsANAN Venture PartnersARARCH Venture PartnersCACasdin CapitalFIFidelity InvestmentsINInvusRORock Springs Capital

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMIMARK IWICKI(Executive Officer, Director)inMFMARTIN FREED(Executive Officer)in

BoardRHROB HOPFNER(Director)in

Co-investorsCACanaan PartnersBABay City CapitalLOLongitude CapitalOROrbiMedRARA Capital

Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.

BiotechHealthtechMedical Devices

CAClarke Atwell(Co-Founder and Chief Operating Officer)in

Co-investorsCACatalio Capital Management, LPRARA CapitalNONovo Holdings

Co-investorsVEVerizon Ventures

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

PRPierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMDMarie De Vulder(Chief Legal Officer Co-founder)inGPGuy Peeters(Chief Financial Officer Co-founder)inJGJohn-Paul Gallivan(Head of Development Co-founder)inFKFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in

Co-investorsLOLongwood FundBABAM ElevateFIFinchley Healthcare VenturesFOForbionLULuma GroupNONovo Holdings+1 more

Crocus Technology, now part of Allegro MicroSystems, develops XtremeSense TMR (Tunnel Magnetoresistance) magnetic sensing technology used in integrated current and position sensor ICs.

Co-investors+N+ND CapitalVEVentechVEVentech ChinaCECEA Investissement

DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas.

BiotechData & InfrastructureHealthtechSaaS

Chris

Co-investorsTITinySeedALAlgerRARA CapitalREREDMILERTRTW Investments L.P.

Entasis Therapeutics is a biotechnology company developing and marketing therapies for critical care and infectious diseases, focusing on serious conditions with high unmet need.

BiotechHealthtech

Sam Holtzman(Founder)in

Co-investorsBOBoulder Ventures

Gilead discovers, develops, and delivers therapeutic medicines for life-threatening diseases, with focus on virology, oncology, and inflammation across 35+ countries.

BiotechHealthtechMedical DevicesPalo Alto, US

Ravindra Majeti(Director)Irving Weissman(Director)EJEric Jensen(Executive Officer)

BoardCSChristopher Schaepe(Director)inJBJeffrey Bird(Director)inDennis Henner(Director)

Co-investorsBLBluebird VenturesLILightspeed Venture Partners

Galera Therapeutics is a biotechnology company developing antibody-based and other therapeutics.

BiotechHealthtechMedical DevicesMalvern, US

MSMel Sorensen(Executive Officer, Director)inJSJoel Sussman(Executive Officer)inJeffery L. Keene(Executive Officer)inDPDennis P. Riley(Executive Officer)inJon T. Holmlund(Executive Officer)RARobert A. Beardsley(Executive Officer, Director)in

Co-investorsNENew Enterprise Associates (NEA)

The site at this domain is a consumer guide to online casinos in Florida, publishing reviews, rankings, and explanations of gambling laws, bonuses, payment methods, and responsible play.

Media & EntertainmentSan Mateo, US

Anukool Lakhina(Executive Officer, Director)

BoardJose Suarez(Director)ASAmit Shah(Director)inBWBrian Wilcove(Director)Andrew Fligel(Director)Michael LaJoie(Director)

Co-investorsQUQuestMark PartnersTRTransLink CapitalARArtiman VenturesGOGoldman SachsINIntel CapitalSISingTel Innov8 Pte Ltd.

Novartis is a pharmaceutical company that develops and commercializes prescription medicines and therapies across therapeutic areas including oncology, cardiovascular disease, and immunology.

BiotechMedical Devices

Co-investorsCACambridge Innovation Capital

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

RLRoy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)ADAmra Demirovic(Chief Human Resources Officer)NHNicole Hadas(Chief Legal Officer)

Co-investorsB B Capital GroupB4B4 CapitalF-F-Prime CapitalALAlexandriaB B CapitalQAQatar Investment Authority+1 more

HealthtechWaltham, US

Adam Gridley(Executive Officer, Director)Peter Greenleaf(Executive Officer, Director)

BoardJoshua Baltzell(Director)Kevin Rakin(Director)Garheng Kong, M.D., Ph.D.(Director)John J. Johnson(Director)

Co-investorsFOFOUNDATION MEDICAL PARTNERSSPSplit Rock Partners

Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.

BiotechDigital HealthMedical DevicesBrisbane, US

CACarlos A. Schuler(Executive Officer, Director)inJSJohn S. Patton(Executive Officer, Director)inRangachari Narasimhan(Executive Officer, Director)GCGrace Colon(Executive Officer, Director)inMiller Samantha(Executive Officer)

BoardMcCarthy Reenie(Director)

Co-investorsASAsset Management CompanyHEHealthCapDEDeerfield Management Company

BiotechBoston, US

ABAxel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)

BoardEdward Mathers(Director)RHRob Hopfner(Director)inMartin Edwards(Director)

Co-investorsLOLongitude CapitalNENew Enterprise Associates (NEA)SASanofi VenturesPIPivotal Life Sciences

daniel welchin

Co-investorsSASanderling Ventures

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

MWMichael W. Dunne(Executive Officer, Promoter)inCNCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)

BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)

Co-investorsBABay City CapitalCACanaan PartnersADAdvent Life SciencesFRFrazier Life SciencesSOSofinnova Venture Partners

Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.

BiotechCambridge, US

KCKim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRMRichard Murray(Executive Officer, Director)

BoardRTRobert Tepper(Director)inCPCary Pfeffer(Director)inRobert Kamen(Director)in

Co-investorsBOBoutique Venture PartnersGEGENERAL INCEPTIONNENextech InvestVEVenture Capital Investment ManagementTHThird Rock Ventures

Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.

Co-investorsARARCH Venture Partners

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.

Advanced ManufacturingBiotechHealthtechMedical Devices

Co-investorsARARCH Venture PartnersCRCross Creek AdvisorsPFPfizer Venture InvestmentsSISignet Healthcare Partners

Co-investorsALAlpha Wave GlobalVEvenBio Partners

BiotechRadnor, US

SBScott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)JHJoe Hulihan, MD(Executive Officer)

BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)

Co-investorsAVAvoro Capital AdvisorsBABain Capital Life SciencesCACanaan PartnersCOConnecticut InnovationsDODomain AssociatesFLFlare Capital Partners+1 more

Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.

BiotechMedical DevicesUtrecht, NL

TLTon Logtenberg(Executive Officer, Director)inMTMark Throsby(Executive Officer)inHLHui Liu(Executive Officer)inJCJohn Crowley(Executive Officer)inLAL. Andres Sirulnik(Executive Officer)inLBLex Bakker(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsPFPfizer Venture InvestmentsRARA Capital

HealthtechNew Orleans, US

MHMark Heiman(Executive Officer)inDale Pfost(Executive Officer, Director, Promoter)

BoardDon Marvin(Director)Richard Montgomery(Director)Ross Barrett(Director)John Elstrott(Director, Promoter)

Co-investorsBABayern KapitalDCDCVC (Data Collective)FEFemHealth VenturesPAPangaea Ventures

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX.

BiotechAustin, US

Co-investorsHIHitecVision Advisory ASLOLongitude CapitalSOSolasta Ventures

Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.

BiotechEvanston, US

Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)

Co-investorsCOCota CapitalECEcoR1 CapitalLALatterell Venture PartnersADAdams Street Partners

BiotechCambridge, US

RGRichard Gaynor, M.D.(Executive Officer)inRobert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)inEric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Co-investorsNENextech InvestCLClal Biotechnology IndustriesTHThird Rock Ventures

Medical DevicesNew Jersey, US

Co-investorsBABay City CapitalF-F-Prime Capital

NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.

BiotechDigital HealthHealthtech

Co-investorsNENew Science VenturesVEvenBio PartnersYSYsios CapitalBGBGVNONovo HoldingsFOForbion

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

ATArthur T. Sands(Executive Officer, Director)inGMGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)inMark Goldsmith(Director)

Co-investorsBABain Capital Life SciencesECEcoR1 CapitalFOForesite CapitalTHThe Column Group

The page is a Vietnamese-language sports streaming site (90Phut TV / 90Phutr.tv, also called Vaoroi TV) offering free live football streaming links, match schedules, standings, results, news, and betting odds.

Media & EntertainmentSports TechHà Nội, VN

Co-investorsAIAisling CapitalM M VenturesNENew Enterprise Associates (NEA)SOSofinnova Partners

Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions.

BiotechDigital HealthHealthtechMedical DevicesBedford, US

ASAmarpreet Sawhney(Director)Kevin Hanley(Executive Officer)Michael Goldstein(Executive Officer)inDBDaniel Bollag(Executive Officer)Antony Mattessich(Executive Officer, Director)inDNDonald Notman(Executive Officer)in

Co-investorsASAscension VenturesSVSV Health InvestorsTOTop Corner CapitalAGAgent Capital

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.

BiotechMedical DevicesNew York, US

Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)Bing Yuan, Ph.D., MBA(Co-Founder, Chief Executive Officer)Eric Slosberg, Ph.D.(Co-Founder, Chief Development Officer)Andy Fu, PharmD, MBA(Co-Founder, Chief Business Officer)

Co-investorsOROrbiMedCACatalio Capital Management, LPF-F-Prime CapitalINInsight PartnersNVNVIDIA

BiotechNew York, US

DGDavid Guyer(Executive Officer, Director)GSGlenn Sblendorio(Executive Officer, Director)MAMike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)

Co-investorsSVSV Health InvestorsCLClarusSVSV Life Sciences

Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.

BiotechHealthtechLa Jolla, US

PKPreston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)

BoardEckard Weber(Director)Brian H. Dovey(Director)in

Co-investorsCRCross Creek AdvisorsNENew Enterprise Associates (NEA)DODomain AssociatesDODomain Partners

Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression.

BiotechDigital HealthHealthtechMental Health

HealthtechSan Francisco, US

Matthew F. Krummel, Ph.D.(Director)SPSteven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)

BoardMichael Powell(Director)

Co-investorsMIMission Bay CapitalMIMission BiocapitalNENew Enterprise Associates (NEA)OUOUP (Osage University Partners)OROrbiMedSOSofinnova Venture Partners

BiotechSouth San Francisco, US

MBMARTIN BABLER(Executive Officer, Director)in

BoardPTPETER THOMPSON(Director)inSRINIVAS AKKARAJU(Director)MDMICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)

Co-investorsACAccess BiotechnologyMIMission BiocapitalMIMission Bay CapitalNENew Leaf Venture PartnersOROrbiMedSASamsara BioCapital+1 more

BiotechMalvern, US

Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)

BoardJames W. Broderick, M.D.(Director)GMGeert-Jan Mulder(Director)inJFJohn Friedman(Director)inHarold R. Werner(Director)

Co-investorsEAEaston CapitalEAEaston Capital Investment GroupFOForbion

BiotechHealthtechMedical DevicesNew York, US

Charles Pfizer

BiotechLa Jolla, US

Allison E. Hulme(Executive Officer, Director)inRERandall E. Woods(Executive Officer, Director)inPeter T. Slover(Executive Officer)Gerald T Proehl(Director)John E Geltosky(Director)Jim E. Heppell(Director)

Spark Therapeutics, now part of the Roche Group, focuses on delivering therapies to improve patient outcomes and create healthier communities.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsFOFountain Healthcare Partners